Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL SARL PHARM ASSIST : revenue, balance sheet and financial ratios

SPFPL SARL PHARM ASSIST is a French company founded 8 years ago, specialized in the sector Activités des sociétés holding. Based in GONNEVILLE-SUR-MER (14510), this company of category PME shows in 2022 a net income positive of 85 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL SARL PHARM ASSIST (SIREN 833546922)
Indicator 2022 2021 2020 2019 2018
Revenue N/C N/C N/C N/C N/C
Net income 84 653 € 83 887 € 221 827 € 83 372 € 82 833 €
EBITDA -2 248 € -2 962 € -1 919 € -1 781 € -3 158 €
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

In 2022, SPFPL SARL PHARM ASSIST generates positive net income of 85 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2022: 83 k€ -> 85 k€.

EBITDA (2022) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-2 248 €

EBIT (2022) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-2 248 €

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

84 653 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 159%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 38%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 9.9 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

159.13%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

38.072%

Repayment capacity (2022) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

9.874

Solvency indicators evolution
SPFPL SARL PHARM ASSIST

Sector positioning

Debt ratio
159.13 2022
2020
2021
2022
Q1: 0.1
Med: 13.78
Q3: 79.91
Average

In 2022, the debt ratio of SPFPL SARL PHARM ASSIST (159.13) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
38.07% 2022
2020
2021
2022
Q1: 21.11%
Med: 62.06%
Q3: 90.2%
Average +7 pts over 3 years

In 2022, the financial autonomy of SPFPL SARL PHARM ASSIST (38.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
9.87 years 2022
2020
2021
2022
Q1: 0.0 years
Med: 0.1 years
Q3: 3.28 years
Average

In 2022, the repayment capacity of SPFPL SARL PHARM ASSIST (9.87) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 493.92. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

493.921

Interest coverage (2022) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-209.119

Liquidity indicators evolution
SPFPL SARL PHARM ASSIST

Sector positioning

Liquidity ratio
493.92 2022
2020
2021
2022
Q1: 111.66
Med: 499.96
Q3: 2835.13
Average

In 2022, the liquidity ratio of SPFPL SARL PHARM ASSIST (493.92) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-209.12x 2022
2020
2021
2022
Q1: -53.22x
Med: 0.0x
Q3: 0.0x
Average

In 2022, the interest coverage of SPFPL SARL PHARM ASSIST (-209.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positioning of SPFPL SARL PHARM ASSIST in its sector

Comparison with sector Activités des sociétés holding

Valuation estimate

Based on 70 transactions of similar company sales in 2022, the value of SPFPL SARL PHARM ASSIST is estimated at 314 050 € (range 101 612€ - 637 724€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2022
70 tx
101k€ 314k€ 637k€
314 050 € Range: 101 612€ - 637 724€
NAF 5 année 2022

Valuation method used

Net Income Multiple
84 653 € × 3.7x = 314 050 €
Range: 101 613€ - 637 725€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 70 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités des sociétés holding)

Compare SPFPL SARL PHARM ASSIST with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sociétés holding

Frequently asked questions about SPFPL SARL PHARM ASSIST

What is the revenue of SPFPL SARL PHARM ASSIST ?

The revenue of SPFPL SARL PHARM ASSIST is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL SARL PHARM ASSIST profitable?

Yes, SPFPL SARL PHARM ASSIST generated a net profit of 85 k€ in 2022.

Where is the headquarters of SPFPL SARL PHARM ASSIST ?

The headquarters of SPFPL SARL PHARM ASSIST is located in GONNEVILLE-SUR-MER (14510), in the department Calvados.

Where to find the tax return of SPFPL SARL PHARM ASSIST ?

The tax return of SPFPL SARL PHARM ASSIST is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL SARL PHARM ASSIST operate?

SPFPL SARL PHARM ASSIST operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.